Selective serotonin reuptake inhibitors in the treatment of depression

A. C. Furman, C. B. Nemeroff

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Selective serotonin reuptake inhibitors (SSRIs) comprise a relatively new class of antidepressants that are believed to act largely by blocking serotonin (5-HT) reuptake into presynaptic nerve terminals in the central nervous system. Widely prescribed throughout the world, SSRIs have a much more favourable side-effect profile than tricyclic antidepressants (TCAs) or monoamine oxidase inhibitors (MAOIs), Their efficacy vs. placebo has been well established and, in general, they exhibit comparable efficacy to tricyclic antidepressants. Controversy still exists as to whether the SSRIs are as efficacious as the TCAs in severe depression including melancholia. Differences do exist between the SSRIs in terms of their pharmacokinetic characteristics, inhibition of various hepatic cytochrome P450 isoenzymes, and side-effect profile, though they are better tolerated than TCAs and MAOIs.

Original languageEnglish (US)
Pages (from-to)101-108
Number of pages8
JournalExpert opinion on investigational drugs
Issue number1
StatePublished - 1996
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Selective serotonin reuptake inhibitors in the treatment of depression'. Together they form a unique fingerprint.

Cite this